D. Muller

发表

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jaana M. Hartikainen, W. Chung, 2019, Nature Genetics.

Differential expression profiling of head and neck squamous cell carcinoma (HNSCC)

L. Bracco, B. Wasylyk, J. Abecassis, 2003, British Journal of Cancer.

Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization.

C. Clavel, M. Polette, P. Birembaut, 1991, Invasion & metastasis.

Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display

L. Bracco, A. Carles, D. Dembélé, 2006, Oncogene.

BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.

J. Simard, D. Yannoukakos, J. Peyrat, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

BRCA 1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA 1 GermLine Mutations 1

J. Simard, D. Yannoukakos, J. Peyrat, 2003 .

Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance.

B. Wasylyk, T. Frebourg, J. Abecassis, 2001, Oral oncology.

Expression of collagenase‐related metalloproteinase genes in human lung or head and neck tumours

J. Abecassis, R. Millon, D. Muller, 1991, International journal of cancer.

The contribution of germline rearrangements to the spectrum of BRCA2 mutations

P. Chappuis, R. Lidereau, D. Stoppa-Lyonnet, 2006, Journal of Medical Genetics.

Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer

A. Spurdle, R. Brandão, D. Stoppa-Lyonnet, 2018, Oncotarget.

University of Southern Denmark Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer French COVAR group collaborators

Sophie, Krieger, R. Brandão, 2018 .

Aalborg Universitet Full in-frame exon 3 skipping of BRCA 2 confers high risk of breast and / or ovarian cancer

Sophie, Krieger, R. Brandão, 2018 .

An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition

I. Bièche, R. Lidereau, J. Abecassis, 2011, BMC Medical Genetics.

A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

F. Révillion, Chloé-Agathe Azencott, N. Sevenet, 2020, BMC Medical Research Methodology.

Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers?

T. Petit, J. Fricker, J. Rodier, 2007 .

Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.

J. Simard, D. Yannoukakos, J. Peyrat, 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Common BRCA 2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA 1 Mutation Carriers

J. Simard, D. Yannoukakos, J. Peyrat, 2005 .

[Germ-line mutations of the BRCA1 gene in northeastern France].

T. Petit, J. Abecassis, J. Fricker, 2000, Bulletin du cancer.

Detection of Prostate-Specific Antigen- or Prostate-Specific Membrane Antigen-Positive Circulating Cells in Prostatic Cancer Patients: Clinical Implications

D. Jacqmin, J. Abecassis, R. Millon, 1999, European Urology.

Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma

B. Wasylyk, J. Abecassis, R. Millon, 2006, British Journal of Cancer.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study

V. Pankratz, F. Couch, B. Bonanni, 2012, British Journal of Cancer.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Mads Thomassen, Stephen Fox, Dieter Niederacher, 2011, Breast Cancer Research.

MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over‐expressed in human breast carcinomas

P. Basset, Y. Lutz, C. Tomasetto, 1997, International journal of cancer.

Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System

F. Révillion, D. Stoppa-Lyonnet, C. Houdayer, 2020, Cancer Research.

Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer.

R. Redon, J. Abecassis, B. Jost, 2002, Cancer research.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays

D. Rickman, A. Reyniès, B. Wasylyk, 2008, Oncogene.

Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers

Peter Devilee, Alfons Meindl, Lesley McGuffog, 2010, Breast Cancer Research.

Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis

Olivier Poch, Frédéric Chalmel, Doulaye Dembélé, 2004, Oncogene.

Mutation analysis of PALB2 gene in French breast cancer families

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2015, Breast Cancer Research and Treatment.

Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome.

J. Abecassis, R. Millon, G. Methlin, 1997, European journal of cancer.

A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.

R. Redon, S. Manoir, J. Abecassis, 2001, Cancer research.

Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas.

R. Lidereau, J. Abecassis, R. Millon, 1994, European journal of cancer. Part B, Oral oncology.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas.

Catherine, P. Basset, J. Abecassis, 1993, Cancer research.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

BRCA Share: A Collection of Clinical BRCA Gene Variants

Christophe Béroud, Dominique Vaur, Izabela Karbassi, 2016, Human mutation.

Cisplatin-induced genes as potential markers for thyroid cancer

J. Abecassis, R. Millon, J. Bergerat, 2004, Cellular and Molecular Life Sciences CMLS.

Modulation of human breast cancer cell adhesion by estrogens and antiestrogens

J. Abecassis, R. Millon, D. Muller, 1989, Clinical & Experimental Metastasis.

BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect

D. Stoppa-Lyonnet, J. Abecassis, J. Fricker, 2004, Familial Cancer.

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene

V. Gaborieau, D. Yannoukakos, J. Peyrat, 2005, International journal of cancer.

The collagenase gene family in humans consists of at least four members.

J. Abecassis, D. Muller, B Quantin, 1988, The Biochemical journal.

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)

G Rennert, N Weerasooriya, K Offit, 2009, British Journal of Cancer.

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study

F. Couch, I. Ellis, T. Rebbeck, 2009, Breast Cancer Research and Treatment.

Adhesion of human breast cancer cell line MCF‐7 to human vascular endothelial cells in culture. enhancement by activated platelets

J. Abecassis, J. Fricker, J. Cazenave, 1987, International journal of cancer.

Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers

V. Pankratz, F. Couch, T. Rebbeck, 2010 .

Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition

I. Bièche, V. Chabaud, J. Peyrat, 2012, Breast Cancer Research and Treatment.

Prophylactic Antibiotics for Urological Procedures

D. Jacqmin, P. Joseph, P. Alken, 1999, European Urology.

The role of cell adhesion and migration in the in vitro invasiveness of mouse adrenal carcinoma cells.

A. F. Scott, M. Penno, D. Muller, 1990, Invasion & metastasis.

Alteration of the C-met oncogene locus in human head and neck-carcinoma.

J. Abecassis, R. Millon, G. Methlin, 1995, Oncology Report.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

A. Whittemore, F. Couch, B. Bonanni, 2015 .